En DE FR ES PL
Famvir - instructions for use, analogs, testimonials and release forms (tablets 125 mg, 250 mg and 500 mg) drugs for the treatment of herpes and shingles in adults, children and pregnancy. Composition

Famvir - instructions for use, analogs, testimonials and release forms (tablets 125 mg, 250 mg and 500 mg) drugs for the treatment of herpes and shingles in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Famvir. Presented are reviews of visitors to the site - consumers of this medication, as well as the opinions of physicians specialists on the use of Famvir in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Famvir in the presence of existing structural analogs. Use to treat herpes and shingles in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

 

Famvir - antiviral drug. After oral famciclovir is rapidly converted to penciclovir, which has activity against human herpes viruses including Varicella zoster virus (herpes zoster virus) and Herpes simplex types 1 and 2 (labial and genital herpes simplex virus), and Epstein-Barr virus and cytomegalovirus .

 

Penciclovir gets in virus-infected cells, which under the action of the viral thymidine kinase is rapidly converted to monophosphate which, in turn, with the participation of cellular enzymes to the triphosphate passes. Penciclovir triphosphate is found in virus-infected cells for more than 12 hours, suppressing the replication of viral DNA in them.

 

The concentration of penciclovir triphosphate in uninfected cells does not exceed the minimum determined, therefore in therapeutic concentrations penciclovir does not affect uninfected cells.

 

Penciclovir is active against recently detected aciclovir-resistant strains of the Herpes simplex virus with altered DNA polymerase.

 

The incidence of resistance to famciclovir (penciclovir) does not exceed 0.3%, in patients with impaired immunity it is 0.19%.

 

Resistance was detected at the beginning of treatment and did not develop during treatment or after the termination of therapy. It has been shown that famciclovir significantly reduces the severity and duration of postherpetic neuralgia in patients with herpes zoster.

 

It has been shown that in patients with impaired immunity due to HIV infection, famciclovir 500 mg twice a day reduces the number of days of isolating the herpes simplex virus (both with clinical manifestations and without them).

 

Composition

 

Famciclovir + excipients.

 

Pharmacokinetics

 

After oral administration, Famvir is rapidly and almost completely absorbed and rapidly converted into active penciclovir. Bioavailability of penciclovir after oral administration of Famvir is 77%. The binding to plasma proteins of penciclovir and its 6-deoxy precursor is less than 20%. At repeated receptions of a preparation of a cumulation it is not noted. Famciclovir is excreted mainly in the form of penciclovir and its 6-deoxy progenitor, which are excreted in the urine unchanged; famciclovir in the urine is not detected.

 

Indications

  • infections caused by the virus Varicella zoster (herpes zoster), including ophthalmoherpes and postherpetic neuralgia;
  • infections caused by the Herpes simplex virus (type 1 and 2): primary infection, exacerbation of chronic infection, suppression of recurrent infection (for the prevention of exacerbations);
  • infections caused by the viruses Varicella zoster and Herpes simplex (type 1 and 2) in patients with reduced immunity.

 

Forms of release

 

Tablets coated with 125 mg, 250 mg and 500 mg.

 

Other dosage forms, be it ointment, cream or solution at the time of publication of the drug in the Directory, did not exist.

 

Instructions for use and dosage

 

The drug is taken orally, regardless of food intake, without chewing, washing with water.

 

Infections caused by the Varicella zoster virus in patients with normal immunity

 

The recommended dose is 250 mg 3 times a day, or 500 mg twice a day, or 750 mg once a day, for 7 days (acute phase of the disease). With ophthalmoherpes, the recommended dose is 500 mg 3 times a day for 7 days. To reduce the duration and frequency of postherpetic neuralgia, the recommended dose is 250-500 mg 3 times a day for 7 days.

 

Infections caused by the Varicella zoster virus in patients with reduced immunity

 

The recommended dose is 500 mg 3 times a day for 10 days.

 

Infections caused by the Herpes simplex virus type 1 and 2, in patients with normal immunity

 

With a primary infection, the recommended dose is 250 mg 3 times a day for 5 days. Treatment should be started as soon as possible, immediately after the appearance of the first symptoms of the disease.

 

With recurrences of chronic infection, adults are prescribed 125 mg twice a day for 5 days. Treatment should begin already in the prodromal period or immediately after the onset of symptoms of the disease.

 

Infections caused by the Herpes simplex virus type 1 and 2, in patients with reduced immunity

 

The recommended dose is 500 mg twice a day for 7 days. Treatment should be started as soon as possible, immediately after the appearance of the first symptoms of the disease.

 

As a suppressive therapy for recurrent herpetic infection 250 mg 2 times a day are prescribed. The duration of therapy depends on the severity of the disease. It is recommended that the drug be taken periodically every 12 months to assess possible changes in the course of the disease. In HIV-infected patients, the effective dose is 500 mg twice a day.

 

Patients of advanced age. If the renal function is preserved, the dose of famciclovir does not change.

 

Patients with impaired renal function.In patients with impaired renal function, there is a decrease in clearance of penciclovir.

 

Patients with violations of the function of the liver dose adjustment is not required.

 

Side effect

  • thrombocytopenia;
  • headache;
  • confusion (mainly in elderly patients);
  • dizziness;
  • drowsiness (mainly in elderly patients);
  • hallucinations;
  • nausea, vomiting;
  • jaundice;
  • rash;
  • itching;
  • hives;
  • severe skin reactions (including erythema multiforme).

 

Contraindications

  • hypersensitivity to famciclovir or any of the components of the drug;
  • hypersensitivity to penciclovir.

 

Application in pregnancy and lactation

 

Because Famvir's safety in pregnant and lactating women has not been studied, its use in pregnancy and lactation is not recommended unless the possible benefits of treatment exceed the potential risk.

 

It is not known whether penciclovir is excreted in human milk.

 

Famciclovir does not have a pronounced effect on spermogram, morphology or motility of human spermatozoa.

 

In experimental studies, embryotoxic and teratogenic effects of famciclovir and penciclovir have not been revealed.

 

Studies on rats administered famciclovir orally showed that penciclovir is excreted in breast milk.

 

A decrease in fertility was noted in the experimental model in male rats receiving famciclovir at a dose of 500 mg / kg of body weight, in female rats, a pronounced decrease in fertility was not observed.

 

Use in children

 

The effectiveness and safety of Famvir in children is not established. Thus, famciclovir is not recommended in children, except when the expected benefit of the treatment justifies the potential risk associated with the use of the drug.

 

Application in elderly patients

 

Patients of advanced age. If the renal function is preserved, the dose of famciclovir does not change.

 

special instructions

 

Treatment should be started immediately after diagnosis.

 

Caution should be exercised in the treatment of patients with impaired renal function, which may require correction of the dosing regimen.

 

Special precautions in elderly patients are not required.

 

Genital herpes is a sexually transmitted disease. During relapse, the risk of infection increases.In the presence of clinical manifestations of the disease, even in the case of the initiation of antiviral treatment, patients should avoid sexual contact.

 

During the maintenance treatment with antiviral agents, the frequency of the spread of the viral infection is significantly reduced, but the risk of transmission of infection theoretically exists. Therefore, patients should take appropriate protective measures during sexual intercourse.

 

The tablets of the drug 125 mg, 250 mg and 500 mg include lactose (26.9 mg, 53.7 mg and 107.4 mg respectively). Famvir should not be used in patients with rare hereditary disorders associated with intolerance to galactose, severe lactase deficiency, or glucose-galactose malabsorption.

 

Carried doses of Famvir and duration of treatment. Famvir was well tolerated in the treatment of infection caused by the virus Varicella zoster, when administered at a dose of 750 mg 3 times a day for 7 days; in patients with genital herpes when using the drug in a dose of 750 mg 3 times a day for 5 days and at a dose of up to 500 mg 3 times a day for 10 days. It was also shown that the drug was well tolerated when taken 250 mg 3 times a day for 12 months to treat genital herpes.Famvir was well tolerated in patients with reduced immunity in the treatment of infection caused by the virus Varicella zoster, when taken 500 mg 3 times a day for 10 days, as well as infections caused by Herpes simplex viruses, when taken up to 500 mg twice a day for 7 days or 500 mg twice a day for 8 weeks.

 

Impact on the ability to drive vehicles and manage mechanisms

 

It is not expected that Famvir will influence the ability of patients to drive a car and other mechanisms, but patients who experience dizziness, drowsiness, confusion, or other CNS abnormalities should not refrain from driving a car or controlling the mechanisms during the use of the drug.

 

Drug Interactions

 

Clinically significant pharmacokinetic interaction Famvir with other drugs was not noted. No effect of famciclovir on the cytochrome P450 system was detected.

 

Drugs that block tubular secretion can increase the concentration of penciclovir in plasma.

 

In the course of the clinical studies, no interaction of zidovudine and famciclovir was observed during their joint administration.

 

Analogues of Famvir

 

Structural analogs for the active substance:

  • Minaker;
  • Famciclovir.

 

Analogues on the curative effect (agents for the treatment of herpes simplex):

  • Amiksin;
  • Anaferon;
  • Anaferon child;
  • Antigerpes;
  • Arbidol;
  • Acyclovir;
  • Walogard;
  • Valtrex;
  • Valtsikon;
  • Vectavir;
  • Virazole;
  • Wirdel;
  • Virolex;
  • Virosept;
  • Vitaherpavak;
  • Viferon;
  • Galavit;
  • Gevisos;
  • Gerpevir;
  • Herpes;
  • Herpferon;
  • Groprinosin;
  • Devirs;
  • Zovirax;
  • Isoprinosine;
  • Immunomax;
  • Kagocel;
  • Kipferon;
  • Lavomax;
  • Lycopid;
  • Neovir;
  • Panavir;
  • Supperan;
  • Ferrovir;
  • Cyclovax;
  • Cyclovir;
  • Cycloviral;
  • Cytivir;
  • Epigenum sex;
  • Erazaban;
  • Ergoferon.

Similar medicines:

Other medicines:

Reviews (1):
Guests
Alla Sergeevna.
I often have herpes on my lips after hypothermia. She was saved by various ointments. But when herpes appeared on the abdomen (I thought it was deprived), I had to see a dermatologist. The doctor assigned me a famvir tablet. Tablets have helped well, herpes though not from the first day, but has passed quickly. Saw a course, side effects I did not have, so I was satisfied.

Rules for publishing reviews and visitor questions